Terms: = Thyroid cancer AND PML, TRIM19, 5371, ENSG00000140464, MYL, PP8675, RNF71 AND Treatment
4 results:
1. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.
Liu J; Wang Y; Tian Z; Lin Y; Li H; Zhu Z; Liu Q; Su S; Zeng Y; Jia W; Yang Y; Xu S; Yao H; Jiang W; Song E
Nat Commun; 2022 May; 13(1):3011. PubMed ID: 35641481
[TBL] [Abstract] [Full Text] [Related]
2. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
3. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract] [Full Text] [Related]
4. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation.
Labelle Y; Zucman J; Stenman G; Kindblom LG; Knight J; Turc-Carel C; Dockhorn-Dworniczak B; Mandahl N; Desmaze C; Peter M
Hum Mol Genet; 1995 Dec; 4(12):2219-26. PubMed ID: 8634690
[TBL] [Abstract] [Full Text] [Related]
